Why is Medicamen Biotec falling/rising?

As of 16-Sep, Medicamen Biotech Ltd is experiencing a decline in its stock price, currently at Rs. 338.00, which reflects a decrease of 5.0 points or 1.46%. The stock has recently hit a new 52-week low and has underperformed its sector by 1.74%. Over the past week, it has fallen by 1.49%, and its year-to-date performance shows a significant decline of 33.63%. The stock has been losing value for the last two days, with a total drop of 2.03%. Additionally, it is trading below all major moving averages, indicating a bearish trend. Despite a low debt-to-equity ratio and a fair valuation compared to peers, the stock's performance has been hindered by poor long-term growth, as evidenced by a negative annual operating profit growth rate of 12.66% over the last five years.
In the broader market context, the Sensex has shown a positive return of 1.58% over the past week, contrasting sharply with Medicamen Biotech's decline. The company has consistently underperformed against the benchmark over the last three years, with a return of -29.36% in the past year compared to the Sensex's slight decrease of 0.73%. This persistent underperformance, coupled with falling investor participation and liquidity issues, suggests a lack of confidence among investors. Overall, the combination of negative stock-specific factors and a contrasting positive market environment contributes to the ongoing decline in Medicamen Biotech's stock price.